| Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial MN Kosiborod, R Esterline, RHM Furtado, J Oscarsson, SB Gasparyan, ... The lancet Diabetes & endocrinology 9 (9), 586-594, 2021 | 112 | 2021 |
| Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the … M Kosiborod, O Berwanger, GG Koch, F Martinez, O Mukhtar, S Verma, ... Diabetes, Obesity and Metabolism 23 (4), 886-896, 2021 | 39 | 2021 |
| Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF PS Jhund, P Ponikowski, KF Docherty, SB Gasparyan, M Böhm, ... Circulation 143 (20), 1962-1972, 2021 | 30 | 2021 |
| Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, ... Nature Medicine 28 (9), 1956-1964, 2022 | 29 | 2022 |
| Adjusted win ratio with stratification: calculation methods and interpretation SB Gasparyan, F Folkvaljon, O Bengtsson, J Buenconsejo, GG Koch Statistical Methods in Medical Research 30 (2), 580-611, 2021 | 22 | 2021 |
| Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials SB Gasparyan, EK Kowalewski, F Folkvaljon, O Bengtsson, ... Journal of Biopharmaceutical Statistics 31 (6), 765-787, 2021 | 10 | 2021 |
| Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: an analysis of the DARE-19 randomized controlled trial HJL Heerspink, RHM Furtado, O Berwanger, GG Koch, F Martinez, ... Clinical Journal of the American Society of Nephrology 17 (5), 643-654, 2022 | 5 | 2022 |
| Second order asymptotical efficiency for a Poisson process SB Gasparyan Journal of Contemporary Mathematical Analysis 50, 98-106, 2015 | 5 | 2015 |
| On approximation of the BSDE with unknown volatility in forward equation S Gasparyan, Y Kutoyants Armenian Journal of Mathematics 7 (1), 59-79, 2015 | 4 | 2015 |
| Design and analysis of studies based on hierarchical composite endpoints: Insights from the DARE-19 Trial SB Gasparyan, J Buenconsejo, EK Kowalewski, J Oscarsson, ... Therapeutic Innovation & Regulatory Science 56 (5), 785-794, 2022 | 3 | 2022 |
| Comments on “Sample size formula for a win ratio endpoint” by RX Yu and J. Ganju SB Gasparyan, EK Kowalewski, GG Koch Statistics in Medicine 41 (14), 2688-2690, 2022 | 2 | 2022 |
| An example of one-step MLE-process in volatility estimation problem SB Gasparyan, YA Kutoyants Հայաստանի ԳԱԱ Տեղեկագիր. Մաթեմատիկա 50 (3), 71-76, 2015 | 1 | 2015 |
| The maraca plot: A novel visualization of hierarchical composite endpoints M Karpefors, D Lindholm, SB Gasparyan Clinical Trials, 17407745221134949, 2022 | | 2022 |
| On the lower bound in second order estimation for Poisson processes: Asymptotic efficiency SB Gasparyan, YA Kutoyants Mathematical Methods of Statistics 26, 1-19, 2017 | | 2017 |
| Two problems of statistical estimation for stochastic processes S Gasparyan Université du Maine; Université d'Etat d'Erevan, 2016 | | 2016 |
Mikhail KosiborodSaint Luke's Mid America Heart InstituteVerified email at saint-lukes.org
